Literature DB >> 35082161

SCARF1-Induced Efferocytosis Plays an Immunomodulatory Role in Humans, and Autoantibodies Targeting SCARF1 Are Produced in Patients with Systemic Lupus Erythematosus.

April M Jorge1, Taotao Lao1, Rachel Kim1, Samantha Licciardi2, Joseph El Khoury1, Andrew D Luster1, Terry K Means1,3, Zaida G Ramirez-Ortiz4,2.   

Abstract

Deficiency in the clearance of cellular debris is a major pathogenic factor in the emergence of autoimmune diseases. We previously demonstrated that mice deficient for scavenger receptor class F member 1 (SCARF1) develop a lupus-like autoimmune disease with symptoms similar to human systemic lupus erythematosus (SLE), including a pronounced accumulation of apoptotic cells (ACs). Therefore, we hypothesized that SCARF1 will be important for clearance of ACs and maintenance of self-tolerance in humans, and that dysregulation of this process could contribute to SLE. In this article, we show that SCARF1 is highly expressed on phagocytic cells, where it functions as an efferocytosis receptor. In healthy individuals, we discovered that engagement of SCARF1 by ACs on BDCA1+ dendritic cells initiates an IL-10 anti-inflammatory response mediated by the phosphorylation of STAT1 and STAT3. Unexpectedly, there was no significant difference in SCARF1 expression in samples of patients with SLE compared with healthy donor samples. However, we detected anti-SCARF1 autoantibodies in 26% of patients with SLE, which was associated with dsDNA Ab positivity. Furthermore, our data show a direct correlation of the levels of anti-SCARF1 in the serum and defects in the removal of ACs. Depletion of Ig restores efferocytosis in SLE serum, suggesting that defects in the removal of ACs are partially mediated by SCARF1 pathogenic autoantibodies. Our data demonstrate that human SCARF1 is an AC receptor in dendritic cells and plays a role in maintaining tolerance and homeostasis.
Copyright © 2022 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35082161      PMCID: PMC8852219          DOI: 10.4049/jimmunol.2100532

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  74 in total

1.  Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.

Authors:  Katja G Weinacht; Louis-Marie Charbonnier; Fayhan Alroqi; Ashley Plant; Qi Qiao; Hao Wu; Clement Ma; Troy R Torgerson; Sergio D Rosenzweig; Thomas A Fleisher; Luigi D Notarangelo; Imelda C Hanson; Lisa R Forbes; Talal A Chatila
Journal:  J Allergy Clin Immunol       Date:  2017-01-27       Impact factor: 10.793

2.  Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells.

Authors:  Kristina Larsson; Malin Lindstedt; Carl A K Borrebaeck
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

Review 3.  The Dynamics of Apoptotic Cell Clearance.

Authors:  Michael R Elliott; Kodi S Ravichandran
Journal:  Dev Cell       Date:  2016-07-25       Impact factor: 12.270

4.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

5.  Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1.

Authors:  Elaine Y Chung; Jianguo Liu; Yoichiro Homma; Yunhua Zhang; Andrea Brendolan; Matilde Saggese; Jihong Han; Roy Silverstein; Licia Selleri; Xiaojing Ma
Journal:  Immunity       Date:  2007-12       Impact factor: 31.745

6.  Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fcgamma receptor-dependent mechanism.

Authors:  Esther Reefman; Gerda Horst; Marije T Nijk; Pieter C Limburg; Cees G M Kallenberg; Marc Bijl
Journal:  Arthritis Rheum       Date:  2007-10

Review 7.  Efferocytosis in health and disease.

Authors:  Amanda C Doran; Arif Yurdagul; Ira Tabas
Journal:  Nat Rev Immunol       Date:  2019-12-10       Impact factor: 53.106

8.  C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition.

Authors:  Helena Païdassi; Pascale Tacnet-Delorme; Virginie Garlatti; Claudine Darnault; Berhane Ghebrehiwet; Christine Gaboriaud; Gérard J Arlaud; Philippe Frachet
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

9.  Involvement of beta-chemokines in the development of inflammatory demyelination.

Authors:  Ileana Banisor; Thomas P Leist; Bernadette Kalman
Journal:  J Neuroinflammation       Date:  2005-02-24       Impact factor: 8.322

10.  Impaired clearance of early apoptotic cells mediated by inhibitory IgG antibodies in patients with primary Sjögren's syndrome.

Authors:  Menelaos N Manoussakis; George E Fragoulis; Aigli G Vakrakou; Haralampos M Moutsopoulos
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

View more
  1 in total

Review 1.  Drugging the efferocytosis process: concepts and opportunities.

Authors:  Parul Mehrotra; Kodi S Ravichandran
Journal:  Nat Rev Drug Discov       Date:  2022-06-01       Impact factor: 112.288

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.